
STELARA IV®
STELARA IV® (Ustekinumab) is an immunosuppressive drug that reduces inflammation in the body due to various autoimmune diseases.
STELARA IV® is manufactured by Janssen Biotech.
Administration and Dosage:
For patients with Crohn’s disease, administration of STELARA IV® is a regimen 1 intravenous infusion therapy followed by a maintenance dose of subcutaneous injections every 8 weeks. Patients with Plaque Psoriasis and Psoriatic Arthritis, STELARA IV® is administered subcutaneously at week 1 and then week 4, followed by every 12 weeks regimen.
Common Side Effects:
The more common side effects of STELARA IV® include serious infections, which may require hospitalization, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses.
More information:
Please read the full Prescribing Information and Medication Guide for STELARA IV® and discuss any questions you have with your doctor.
Indication:
STELARA IV® is indicated to treat:
Crohn’s Disease
Plaque Psoriasis
Psoriatic Arthritis
Contact Us
Interested in working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!
Check our Privacy Practice